Controversial Alzheimer’s Drug Takes Step Toward FDA Approval

(Bloomberg) -- Biogen Inc.’s experimental Alzheimer’s disease treatment aducanumab was granted priority review status by U.S. regulators, a move that could hasten the drug’s arrival on the market.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.